SEC Form 4 · accession 0001179110-17-002931
ABBOTT LABORATORIES · ABT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Deepak S. Nath
Officer — Senior Vice President
Period of report
Feb 17, 2017
Accepted (ET)
Feb 22, 2017 · 5:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000001800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common shares without par valueF1 | Feb 17, 2017 | A | 11,089 | $0.00 | A | 58,471 | D | |
| Common shares without par value | Feb 21, 2017 | F | 819 | $44.69 | D | 57,652 | D | |
| Common shares without par value | Feb 21, 2017 | S | 319 | $44.981 | D | 57,333 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F2 | $44.40 | Feb 17, 2017 | A | 76,693 | A | Feb 17, 2018 | Feb 16, 2027 | Common shares | 76,693 | 76,693 | D |
Explanation of responses
- F1These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
- F2Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,565 on 2/17/2018, 25,564 on 2/17/2019, and 25,564 on 2/17/2020.
Remarks
The sale transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1(c).